Skip to Content
 

VICC toll-free number 1-877-936-8422

Clinical Trials for XL184

1 Open Trial

    Trial Type Protocol No. &
    Open Date
    Summary

    Treatment

    VICCURO1687

    01/31/2017

    A Phase 1, Multiple-Dose, Dose-Escalation Trial of PT2385 Tablets, a HIF-2α Inhibitor in Patients with Advanced Clear Cell Renal Cell Carcinoma


    Print this page for your doctor